ROYALTY PHARMA PLC - CLASS A (RPRX)

Fideuram Intesa Sanpaolo Private Banking S.P.A. trimmed its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 92.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,158 shares of the bi

Moran Wealth Management LLC raised its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 28.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 175,822 shares of the biopharmaceu

Inspire Investing LLC cut its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 82.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,093 shares of the biopharmaceutical company's stock af

Marshall Urist, the EVP of $RPRX, sold 9,099 shares of the company on 07-01-2026 for an estimated $508,453. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their shares of this class of stock. Following this trade, they now own 0 shares of ...

Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its current checks still point to a stock that screens as expensive rather than clearly cheap. Over the past 5 years, Recursion Pharmaceuticals shareholders have seen the ...